belantamab mafodotin联合泊马度胺和地塞米松对比硼替佐米联合泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤的患者报告结局(DREAMM-8):3期开放标签随机对照试验
DREAMM-8试验在18个国家95个中心纳入302例来那度胺暴露的复发或难治性多发性骨髓瘤患者,1:1随机接受belantamab mafodotin联合泊马度胺和地塞米松(155例)或硼替佐米联合泊马度胺和地塞米松(147例)。治疗期间患者报告的健康相关生活质量在两组均保持稳定,belantamab mafodotin组在多数访视点达到≥10分有意义改善的患者比例持续高于硼替佐米组;两组副作用在治疗第一年内困扰程度均轻微。
要点
- 两组患者报告的健康相关生活质量在治疗期间均保持稳定。
- belantamab mafodotin组在多数访视点达到≥10分有意义改善的患者比例持续高于硼替佐米组。
- 视力模糊是最常报告为严重或非常严重的不良事件,belantamab mafodotin组146例中63例(43%),硼替佐米组139例中13例(9%)。
核心结论
- 接受belantamab mafodotin联合泊马度胺和地塞米松或硼替佐米联合泊马度胺和地塞米松治疗的患者报告健康相关生活质量稳定。
- 自我报告的眼部不良事件在治疗第一年内总体可控且困扰程度轻微。
- 这些发现表明belantamab mafodotin联合泊马度胺和地塞米松耐受性良好,对健康相关生活质量损害很小,支持其在复发或难治性多发性骨髓瘤中的应用。
研究设计与样本
- 3期开放标签随机对照试验,在18个国家95个中心进行。
- 纳入302例来那度胺暴露的复发或难治性多发性骨髓瘤成人患者,按1:1随机分配至belantamab mafodotin组(n=155)或硼替佐米组(n=147)。
- belantamab mafodotin组接受28天周期静脉belantamab mafodotin(第1周期第1天2·5 mg/kg,第2周期起第1天1·9 mg/kg)联合口服泊马度胺(4 mg,第1至21天)和口服地塞米松(40 mg,第1、8、15、22天);硼替佐米组接受21天周期皮下硼替佐米(1·3 mg/m2,第1-8周期第1、4、8、11天,第9周期起第1、8天)联合泊马度胺和地塞米松,剂量和方案与belantamab mafodotin组相同。
- 主要患者报告结局终点为健康相关生活质量较基线的变化,采用EORTC QLQ-C30、EORTC QLQ-MY20和PRO-CTCAE测量;眼表疾病指数和FACIT-GP5作为探索性终点。
- EORTC QLQ-C30和QLQ-MY20疾病症状领域在意向治疗人群分析,PRO-CTCAE在安全性人群(至少接受一剂研究治疗的患者)分析。
主要发现
- 2020年10月12日至2022年12月26日,382例患者接受资格评估,80例被排除,302例入组并随机分配至belantamab mafodotin组(n=155)或硼替佐米组(n=147)。
- 全人群中位年龄66·1岁(SD 9·31),302例中男性181例(60%),白人260例(86%)。
- 主要分析数据截止(2024年1月29日)时,中位随访21·8个月(IQR 13·2-27·6)。
- 治疗期间所有患者报告结局评估中,第一年内多数访视的依从性至少90%。
- EORTC QLQ-C30和QLQ-MY20领域评分较基线变化在两组随时间保持稳定,belantamab mafodotin组在多数访视点达到有意义改善(≥10分)的患者比例持续高于硼替佐米组。
临床怎么用
- 原文结论指出belantamab mafodotin联合泊马度胺和地塞米松耐受性良好,对健康相关生活质量损害很小,支持其在复发或难治性多发性骨髓瘤中的应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the DREAMM-8 trial, belantamab mafodotin, pomalidomide, and dexamethasone demonstrated a statistically significant reduction in the risk of progression or death compared with bortezomib, pomalidomide, and dexamethasone in lenalidomide-exposed patients with relapsed or refractory multiple myeloma. We present patient-reported outcomes from this trial. METHODS: This phase 3, open-label, randomised controlled trial was done in 95 sites in 18 countries. Eligible patients were adults aged 18 years or older with relapsed or refractory multiple myeloma per International Myeloma Working Group criteria, an Eastern Cooperative Oncology Group performance status of 0-2, and previous treatment with at least one line of therapy that included lenalidomide. Patients were randomly assigned (1:1) by a central interactive response technology system to receive 28-day cycles of intravenous belantamab mafodotin (2·5 mg/kg on day 1 of cycle 1 and 1·9 mg/kg on day 1 of cycle 2 onward) combined with oral pomalidomide (4 mg on days 1 to 21) and oral dexamethasone (40 mg on days 1, 8, 15, and 22; belantamab mafodotin group) or 21-day cycles of subcutaneous bortezomib (1·3 mg/m2 on days 1, 4, 8, and 11 of cycles 1-8 and days 1 and 8 of cycle 9 onward) combined with pomalidomide and dexamethasone at the same doses and schedules as the belantamab mafodotin group; bortezomib group). Treatment continued until the occurrence of progressive disease, unacceptable adverse effects, withdrawal of consent, or death (whichever occurred first). Secondary patient-reported outcome endpoints were change from baseline in health-related quality of life (HRQOL), measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-MY20, and Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE). Ocular Surface Disease Index and Functional Assessment of Chronic Illness Therapy-Item GP5 results were assessed similarly as exploratory endpoints. EORTC QLQ-C30 and EORTC QLQ-MY20 disease symptom domain results were analysed in the intent-to-treat population, and PRO-CTCAE results were analysed in the safety population (patients who received at least one dose of study treatment). For all patient-reported outcome assessments, proportions included the number and percentage of patients with available data, and changes from baseline were summarised as means with 95% CIs at each timepoint. This trial was registered with ClinicalTrials.gov, NCT04484623, and is ongoing. FINDINGS: Between Oct 12, 2020, and Dec 26, 2022, 382 patients were assessed for eligibility. 80 patients were excluded and 302 patients were enrolled and randomly assigned to either the belantamab mafodotin group (n=155) or bortezomib group (n=147). The median age in the whole population was 66·1 years (SD 9·31). 181 (60%) of 302 patients were male and 260 (86%) were White. At the primary analysis data cutoff (Jan 29, 2024), median follow-up was 21·8 months (IQR 13·2-27·6). For all patient-reported outcome assessments during treatment, compliance was at least 90% for most visits within the first year. Change from baseline in EORTC QLQ-C30 and QLQ-MY20 domain scores remained stable in both treatment groups over time, with a consistently greater proportion of patients in the belantamab mafodotin group than in the bortezomib group experiencing meaningful improvement (≥10 points) at most visits. Side-effects were minimally bothersome in both groups within the first year of treatment. Blurred vision was the adverse event most commonly reported as severe or very severe (63 [43%] of 146 patients in the belantamab mafodotin group and 13 [9%] of 139 patients in the bortezomib group), followed by fatigue (56 [38%] of patients in the belantamab mafodotin group and 49 [35%] of patients in the bortezomib group). No clear differences between groups were observed for other symptomatic adverse events. INTERPRETATION: Patients with relapsed or refractory multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone or bortezomib, pomalidomide, and dexamethasone reported stable HRQOL. Self-reported ocular adverse events were generally manageable and minimally bothersome within the first year of treatment. These findings indicate that belantamab mafodotin, pomalidomide, and dexamethasone is well tolerated, with little detriment to HRQOL, supporting its use in relapsed or refractory multiple myeloma. FUNDING: GSK.
引用
- Dimopoulos MA, Beksac M, Pour L, et al. Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025. PMID: 41193117. doi:10.1016/S2352-3026(25)00256-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。